Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones

被引:68
作者
Ena, J [1 ]
López-Perezagua, MD
Martínez-Peinado, C
Cia-Barrio, AD
Ruíz-López, I
机构
[1] Hosp Marina Baixa, Med Interna Serv, Div Internal Med, Alicante 03570, Spain
[2] Hosp Marina Baixa, Div Microbiol, Alicante, Spain
[3] Hosp Marina Baixa, Pharm Div, Alicante, Spain
关键词
D O I
10.1016/S0732-8893(97)00216-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The evolution (from 1990 to 1996) of fluoroquinolone consumption and resistance and the current patterns of fluoroquinolone usage were examined in a 250-bed community hospital in Spain. Fluoroquinolone consumption increased from 1392 g in 1990 to 3203 g in 1996 (p < 0.05). A significant increase in ciprofloxacin resistance runs observed in Escherichia coli isolated from urine samples (from 3 to 20%, p < 0.00001), but not in those E. coli isolated from blood or other sample cultures. In 69 randomly selected clinical charts, fluoroquinolone was used as prophylaxis, empirical therapy, and specific directed therapy in 20%, 65%, and 15%, respectively. Evaluation of quinolone indication was: first choice agents (29%), alternative agents (49%), experimental agents (4.3%) and, agents with no role (1.4%). Our study shows that the increase in the use of fluoroquinolones is associated with the emergence of ciprofloxacin-resistant E. coli from urinary tract sources. Based on their indications, current quinolone usage can be greatly reduced. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:103 / 107
页数:5
相关论文
共 21 条
[1]  
ALOS JI, 1988, MED CLIN-BARCELONA, V90, P395
[2]  
[Anonymous], M7A2 NCCLS
[3]   URINARY-TRACT INFECTIONS WITH ANTIBIOTIC-RESISTANT ORGANISMS IN CATHETERIZED NURSING-HOME PATIENTS [J].
BJORK, DT ;
PELLETIER, LL ;
TIGHT, RR .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1984, 5 (04) :173-176
[4]   SYSTEMIC ANTIBIOTIC-THERAPY PREVENTS BACTERIAL-INFECTION IN CIRRHOTIC-PATIENTS WITH GASTROINTESTINAL HEMORRHAGE [J].
BLAISE, M ;
PATERON, D ;
TRINCHET, JC ;
LEVACHER, S ;
BEAUGRAND, M ;
POURRIAT, JL .
HEPATOLOGY, 1994, 20 (01) :34-38
[5]   EMERGENCE OF QUINOLONE-RESISTANT ESCHERICHIA-COLI BACTEREMIA IN NEUTROPENIC PATIENTS WITH CANCER WHO HAVE RECEIVED PROPHYLACTIC NORFLOXACIN [J].
CARRATALA, J ;
FERNANDEZSEVILLA, A ;
TUBAU, F ;
CALLIS, M ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :557-560
[6]   RESISTANCE TO BETA-LACTAM ANTIBIOTICS AND CIPROFLOXACIN IN GRAM-NEGATIVE BACILLI AND STAPHYLOCOCCI ISOLATED FROM BLOOD - A EUROPEAN COLLABORATIVE STUDY [J].
DORNBUSCH, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (02) :269-278
[7]  
DUYPERSON C, 1994, ANTIMICROB AGENTS CH, V38, P340
[8]   RISK-FACTORS FOR ACQUISITION OF URINARY-TRACT INFECTIONS CAUSED BY CIPROFLOXACIN RESISTANT ESCHERICHIA-COLI [J].
ENA, J ;
AMADOR, C ;
MARTINEZ, C ;
DELATABLA, VO .
JOURNAL OF UROLOGY, 1995, 153 (01) :117-120
[9]  
FISH DN, 1992, ARCH INTERN MED, V152, P1328
[10]   MULTICENTER SPANISH STUDY OF CIPROFLOXACIN SUSCEPTIBILITY IN GRAM-NEGATIVE BACTERIA [J].
GARCIARODRIGUEZ, JA ;
FRESNADILLO, MJ ;
GARCIA, MIG ;
GARCIASANCHEZ, E ;
GARCIASANCHEZ, JE ;
TRUJILLANO, I ;
BAQUERO, F ;
BELTRAN, JM ;
BOUZA, E ;
RODRIGUEZ, M ;
BREA, ML ;
PICAZO, JJ ;
SORIANO, F ;
PEREA, E ;
DELAROSA, M ;
PIEDROLA, G ;
LUENGO, FM ;
DELOMAS, JG ;
GOBERNADO, M ;
MARTIN, R ;
PRATS, G ;
LUS, RG ;
AISA, ML ;
CISTERNA, R ;
RIESTRA, CG .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (05) :456-459